EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Aminopeptidase N (CD13): Bridging physiology, pathology and therapeutic potential

Gabriel C Nwokolo, Robert A Falconer, Francis M Barnieh

Advances in Clinical Chemistry · 2025

DOI: 10.1016/bs.acc.2025.07.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Clinical Chemistry, 2025. Verfasst von Gabriel C Nwokolo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom. Hauptthemen laut MEDLINE: CD13 Antigens, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 286 Literaturangaben. Gefördert von: Masonic Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aminopeptidase N (CD13) is a multifunctional protein recognized for its diverse roles as an enzyme, receptor, and signalling molecule, attributes that have earned it classification as a "moonlighting" protein. Its involvement in key biological processes such as inflammation, angiogenesis, cell migration, tissue invasion, and the propagation and survival of cancer cells has spurred significant interest in its potential as a therapeutic target. This interest extends beyond oncology to include conditions such as hypertension and rheumatoid arthritis. Consequently, substantial research efforts have been directed toward exploring strategies for leveraging CD13 in clinical interventions. This chapter comprehensively reviews this protein with the aim of improving current understanding of this protein, with a particular focus on its tissue-specific expression and functional roles. Special attention is given to the physiological and pathological diversity of CD13 activity, which offers critical insights into opportunities for selective targeting and disease-specific therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD13 AntigensNeoplasmsHumansAnimalsInflammationArthritis, Rheumatoid

Stichwörter der Autor:innen

Aminopeptidase NCD13CancerGlycoformsProdrugTargeted therapy

Substanzen

CD13 Antigens

Autor:innen und Institutionen

  • Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom.
  • Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom. Electronic address: r.a.falconer1@bradford.ac.uk.
  • Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom. Electronic address: f.mprahbarnieh1@bradford.ac.uk.

Förderung

  • Masonic Charitable Foundation

Zitieren

APA

Nwokolo, G. C., Falconer, R. A., & Barnieh, F. M. (2025). Aminopeptidase N (CD13): Bridging physiology, pathology and therapeutic potential. Advances in Clinical Chemistry. https://doi.org/10.1016/bs.acc.2025.07.002

Vancouver

Nwokolo GC, Falconer RA, Barnieh FM. Aminopeptidase N (CD13): Bridging physiology, pathology and therapeutic potential. Advances in Clinical Chemistry. 2025. doi:10.1016/bs.acc.2025.07.002

BibTeX
@article{Nwokolo2025,
  author = {Nwokolo, Gabriel C and Falconer, Robert A and Barnieh, Francis M},
  title = {Aminopeptidase N (CD13): Bridging physiology, pathology and therapeutic potential},
  journal = {Advances in Clinical Chemistry},
  year = {2025},
  doi = {10.1016/bs.acc.2025.07.002}
}
Kostenlos starten →